(COLO-B) Coloplast - CO
Sector: Healthcare | Industry: Medical Instruments & Supplies | Exchange: CO (Denmark) | Market Cap: 84.242m DKK | Total Return: -34.6% in 12m
Avg Turnover: 148M
EPS Trend: -57.7%
Qual. Beats: -1
Rev. Trend: 94.7%
Qual. Beats: 0
Warnings
Below Avwap Earnings
Tailwinds
No distinct edge detected
Coloplast A/S is a Denmark-based medical device company specializing in intimate healthcare products across five primary segments: Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Dressings. The firm develops and manufactures specialized consumables including ostomy bags, catheters, voice prostheses, and surgical implants for urological and gynecological disorders. Its portfolio features established brands such as SenSura, SpeediCath, and Biatain.
The company operates within the medical technology sector, characterized by high switching costs and recurring revenue models. Because many of its products are essential daily-use consumables for chronic conditions, the business model relies on long-term patient retention and reimbursement frameworks in developed healthcare markets. The 2022 acquisition of Atos Medical expanded its footprint into the chronic laryngectomy care market, diversifying its respiratory portfolio.
- Chronic Care organic growth driven by SenSura Mio market share gains
- Kerecis acquisition integration scales Advanced Wound Care margins and revenue
- Chronic Care volume growth offsets pricing pressure from European reimbursement reforms
- Interventional Urology expansion in US market diversifies revenue beyond ostomy care
| Net Income: 2.11b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.13 > 0.02 and ΔFCF/TA 2.91 > 1.0 |
| NWC/Revenue: 15.95% < 20% (prev -1.80%; Δ 17.75% < -1%) |
| CFO/TA 0.16 > 3% & CFO 7.59b > Net Income 2.11b |
| Net Debt (24.1b) to EBITDA (11.4b): 2.12 < 3 |
| Current Ratio: 1.75 > 1.5 & < 3 |
| Outstanding Shares: last quarter (225.4m) vs 12m ago -0.01% < -2% |
| Gross Margin: 58.60% > 18% (prev 67.52%; Δ -8.91% > 0.5%) |
| Asset Turnover: 58.55% > 50% (prev 56.55%; Δ 2.00% > 0%) |
| Interest Coverage Ratio: 7.02 > 6 (EBIT TTM 6.97b / Interest Expense TTM 994.0m) |
| A: 0.10 (Total Current Assets 10.5b - Total Current Liabilities 5.98b) / Total Assets 46.6b |
| B: 0.30 (Retained Earnings 14.1b / Total Assets 46.6b) |
| C: 0.15 (EBIT TTM 6.97b / Avg Total Assets 47.9b) |
| D: 0.38 (Book Value of Equity 12.8b / Total Liabilities 33.8b) |
| Altman-Z'' = 2.99 = A |
| DSRI: 0.90 (Receivables 4.97b/5.49b, Revenue 28.0b/27.8b) |
| GMI: 1.15 (GM 67.52% / 58.60%) |
| AQI: 0.95 (AQ_t 0.61 / AQ_t-1 0.65) |
| SGI: 1.01 (Revenue 28.0b / 27.8b) |
| TATA: -0.12 (NI 2.11b - CFO 7.59b) / TA 46.6b) |
| Beneish M = -3.01 (Cap -4..+1) = AA |
As of June 20, 2026, the stock is trading at DKK 378.80 with a total of 625,230 shares traded.
Over the past week, the price has changed by +0.27%,
over one month by -6.68%,
over three months by -14.36% and
over the past year by -34.61%.
Coloplast has no consensus analysts rating.
P/E Trailing = 39.9786
P/E Forward = 14.0845
P/S = 3.0038
P/B = 6.6682
P/EG = 0.9696
Revenue TTM = 28.0b DKK
EBIT TTM = 6.97b DKK
EBITDA TTM = 11.4b DKK
Long Term Debt = 21.3b DKK (from longTermDebt, last quarter)
Short Term Debt = 2.49b DKK (from shortTermDebt, last quarter)
Debt = 25.1b DKK (from shortLongTermDebtTotal, last quarter) + Leases 914.0m
Net Debt = 24.1b DKK (calculated: Debt 25.1b - CCE 1.07b)
Enterprise Value = 108b DKK (84.2b + Debt 25.1b - CCE 1.07b)
Interest Coverage Ratio = 7.02 (Ebit TTM 6.97b / Interest Expense TTM 994.0m)
EV/FCF = 17.95x (Enterprise Value 108b / FCF TTM 6.03b)
FCF Yield = 5.57% (FCF TTM 6.03b / Enterprise Value 108b)
FCF Margin = 21.51% (FCF TTM 6.03b / Revenue TTM 28.0b)
Net Margin = 7.51% (Net Income TTM 2.11b / Revenue TTM 28.0b)
Gross Margin = 58.60% ((Revenue TTM 28.0b - Cost of Revenue TTM 11.6b) / Revenue TTM)
Gross Margin QoQ = 42.95% (prev 67.23%)
Tobins Q-Ratio = 2.32 (Enterprise Value 108b / Total Assets 46.6b)
Interest Expense / Debt = 3.95% (Interest Expense 994.0m / Debt 25.1b)
Taxrate = 38.85% (1.34b / 3.44b)
NOPAT = 4.27b (EBIT 6.97b * (1 - 38.85%))
Current Ratio = 1.75 (Total Current Assets 10.5b / Total Current Liabilities 5.98b)
Debt / Equity = 1.96 (Debt 25.1b / totalStockholderEquity, last quarter 12.8b)
Debt / EBITDA = 2.12 (Net Debt 24.1b / EBITDA 11.4b)
Debt / FCF = 3.99 (Net Debt 24.1b / FCF TTM 6.03b)
Total Stockholder Equity = 14.8b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.40% (Net Income 2.11b / Total Assets 46.6b)
RoE = 14.23% (Net Income TTM 2.11b / Total Stockholder Equity 14.8b)
RoCE = 19.30% (EBIT 6.97b / Capital Employed (Equity 14.8b + L.T.Debt 21.3b))
RoIC = 10.13% (NOPAT 4.27b / Invested Capital 42.1b)
WACC = 5.61% (E(84.2b)/V(109b) * Re(6.56%) + D(25.1b)/V(109b) * Rd(3.95%) * (1-Tc(0.39)))
Discount Rate = 6.56% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 59.81 | Cagr: 1.38%
[DCF] Terminal Value 77.97% ; FCFF base≈5.59b ; Y1≈6.41b ; Y5≈9.43b
[DCF] Fair Price = 568.3 (EV 142b - Net Debt 24.1b = Equity 118b / Shares 207.4m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: -57.68 | EPS CAGR: -6.49% | SUE: -4.0 | # QB: -1
Revenue Correlation: 94.67 | Revenue CAGR: 5.92% | SUE: 0.31 | # QB: 0
EPS current Quarter (2026-06-30): EPS=6.13 | Chg30d=-3.45% | Revisions=-33% | Analysts=5
EPS current Year (2026-09-30): EPS=24.38 | Chg30d=-1.66% | Revisions=-40% | GrowthEPS=+37.3% | GrowthRev=+3.1%
EPS next Year (2027-09-30): EPS=26.28 | Chg30d=-1.41% | Revisions=-71% | GrowthEPS=+7.8% | GrowthRev=+6.9%
[Analyst] Revisions Ratio: -71%